Sight Sciences TearCare wins FDA label expansion to improve meibomian gland function in dry eye patients

Reuters2026/08/19 11:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA updated the TearCare System indication effective Aug. 18, 2026 to include improving meibomian gland function in adult evaporative dry eye.
Label now specifies use with manual meibomian gland expression; optional debridement added as part of the cleared system.
Change expands the product’s permitted marketing claims, potentially strengthening reimbursement and competitive positioning in MGD treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190705PRIMZONEFULLFEED9812581) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sight Sciences TearCare wins FDA label expansion to improve meibomian gland function in dry eye patients

You may also like

Crypto prices